

ESTRO

JANA JAAL

Associate Professor in Oncology, MD, PhD

Tartu University Hospital

Estonia

ESTRO background

2014-2015 ESTRO HERO project: Estonian representative.

2011-... ESTRO representative of National Society (Estonian Society of Clinical Oncologists).

2010-2018 ESTRO conferences: ESTRO29 Scientific Advisory Committee, Clinical Radiotherapy; EIOF1 National Societies Advisory Committee; ESTRO31 Scientific Advisory Committee of Young ESTRO members; EIOF2 Scientific Program Committee; ESTRO37 Scientific Advisory Group for Clinical Radiotherapy.

2010-... ESTRO conference abstract reviewing committees: ESTRO29, ESTRO31, EIOF2, EIOF3, ESTRO37, ESTRO38, ESTRO 2020.

2010-2015 Editorial Board member of the journal "Radiotherapy and Oncology".

2010-2012 ESTRO Clinical Radiotherapy Committee member.

2006 ESTRO/VARIAN Research Award.

2002 First attended ESTRO conference (ESTRO21).

2002-... ESTRO active member.

Experience

Tartu University Hospital:

2018 -... council member of Tartu University Hospital net-hospitals (Valga Hospital, Põlva Hospital, South-Estonian Hospital).

2007-... Tartu University Hospital, Clinic of Hematology and Oncology, clinical oncologist, since 2008 Head of the Dept. of Radiotherapy and Oncological Therapy.

University of Tartu:

2016-... University of Tartu, Faculty of Medicine, Institute of Clinical Medicine, Associate Professor in Oncology, since 2017 Head of the Dept. of Hematology and Oncology.

2008-2011, 2017-... general supervisor of residency program of clinical oncology (radiation and medical oncology combined).

2007-2018 University of Tartu, Faculty of Medicine, Institute of Clinical Medicine, Senior Research Fellow in Oncology.

Other:

2011-... Medical Specialists (UEMS), UEMS section of Radiotherapy and Oncology.

2011-... Estonian Society of Clinical Oncologists, Board leader 2011-2014, Board member since 2015.

ESTRO

2008–... Ministry of Social Affairs of Estonia, adviser of oncology.

2007–... Ministry of Social Affairs of Estonia, Committee for Cancer Treatment Quality, member.

2000–2013 Estonian Society of Oncologists, Board member 2006-2013.

Taken together, I have >12 years of clinical experience (clinical oncologist), teaching and research experience (senior researcher, assistant professor of oncology, general supervisor of residency program of clinical oncology) and experience in the field of oncology (adviser of oncology, cancer treatment quality committee, cancer care organization in the region served by Tartu University Hospital).

Additionally, I have led 3 population based research studies in collaboration with Estonian Society of Clinical Oncologists and Estonian Cancer Registry (The National Institute for Health Development): „Cancer in Young Adults“ (2014), „Cancer in Elderly“ (2015) and „Multiple cancers“ (2018).

Education and Qualifications

Education:

2003-2006 Technical University of Dresden, Faculty of Medicine (PhD, "Radiation effects in the urinary bladder (mouse): Histopathologic features and modification by recombinant human Keratinocyte Growth Factor", supervisor prof Wolfgang Dörr).

1999-2003 University of Tartu, Clinic of Hematology and Oncology, residency of oncology (clinical oncologist, radiation and medical oncology combined).

1998-1999 Tartu University Hospital, internship (general physician).

1992-1998 University of Tartu, Faculty of Medicine (MD).

Honors and awards:

2017 Research Award of Tartu University Hospital.

2015 5-year Publication Award of Tartu University Hospital.

2011 Research Award of Tartu University Hospital.

2007 Award of the Bank of Sampo.

2007 ASTRO Travel Grant winner (American Society for Therapeutic Radiology and Oncology).

2006 Scholar in Training (SIT) Award (Radiation Research Society).

2006 ESTRO/VARIAN Research Award (European Society for Radiotherapy and Oncology).

2005 Young Investigator Award (European Society of Radiobiology).

2003 EDRO (Education for Radiotherapy) Travel Grant 2003 (European Society for Radiotherapy and Oncology).

Topics of interest:

Radiotherapy, radiotherapy-induced side-effects, glioblastoma, lung cancer, immunotherapy, radiotherapy and immunotherapy combinations, stereotactic body radiotherapy in oligometastatic disease, cancer care (early detection, screening, treatment, resources, quality indicators, quality control, palliative care).

ESTRO

Supervised dissertations – 2, dissertations under supervision – 5, publications 129.
For more details, see CV in English (Estonian Research Information System):
https://www.etis.ee/CV/Jana_Jaal/eng

Personal

I have a family with 3 children who have supported me along my all studies and activities involved in the field of oncology.

Final statement

I have been involved in ESTRO since 2002. ESTRO21, held also in 2002, was the first international conference in my life where I presented the first results of my PhD studies on radiation-induced side effects in the urinary bladder. After intensive animal *in vivo* studies on radiation-induced urinary bladder dysfunction, I was awarded ESTRO/VARIAN Research Award in 2006, which has been one of the most remarkable acknowledgements in my life so far. Subsequently, I have been actively involved in different ESTRO activities up to today.

Radiotherapy and oncology are continuously changing. Increasing cancer incidence, higher proportion of older people with cancer, people with multiple cancers as well as a growing need for radiotherapy, are just some important changes. In Estonia, I have been involved in different areas of oncology, such as teaching, research, clinical work as well as governmental oncopolicy. During last years, I have also gained experience in general health care management being council member of Tartu University Hospital net-hospitals and organizing cancer care not only in one hospital but in the whole region. Due to a broad range of experience, I feel that I have something that I can share for the benefit of the society and all people involved.

Radiotherapy is an important curative treatment modality. Moreover, radiotherapy is being incorporated into management of metastatic disease, where it is given to oligometastases in combination with systemic treatments, including immunotherapy. These changes should be clearly addressed in our society, since all specialties involved in the delivery of radiotherapy should be also aware of systemic treatments and their side-effects. Being a clinical oncologist and having experience in both radiotherapy and medical treatments, I am in a good position to facilitate these discussions.

ESTRO has never had a candidate from Baltic states, including Estonia with 1.3 million inhabitants in total. Although it may seem similar on a larger scale, every European country and region has differences and therefore distinct needs and possibilities to fulfill ESTRO strategic priorities stated in ESTRO vision 2030. Similarly to bigger European countries, the voice of smaller members should be heard and taken into consideration.

I hope that you will trust my experience and allow me to contribute to the growth of our society for the benefit of all cancer patients in Europe.